Arrowhead Pharmaceuticals, Inc. (LON:0HI3)
25.14
+3.37 (15.46%)
At close: Sep 2, 2025
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $27.77M USD in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $572.98M, up 2,816.21% year-over-year. In the fiscal year ending September 30, 2024, Arrowhead Pharmaceuticals had annual revenue of $3.55M, down -98.52%.
Revenue (ttm)
$572.98M
Revenue Growth
+2,816.21%
P/S Ratio
6.89
Revenue / Employee
$940.85K
Employees
609
Market Cap
2.88B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Arrowhead Pharmaceuticals News
- 3 days ago - Arrowhead Pharma (ARWR): HC Wainwright Maintains Buy Rating | ARWR Stock News - GuruFocus
- 3 days ago - Arrowhead Pharmaceuticals (ARWR) Enters $2.2 Billion Deal with Novartis - GuruFocus
- 3 days ago - Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
- 3 days ago - Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion - Investor's Business Daily
- 3 days ago - Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy - Seeking Alpha
- 3 days ago - Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy - Reuters
- 3 days ago - Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement - Business Wire
- 9 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences - Business Wire